Autoimmune hepatitis (AIH) is a chronic, progressive, immune-mediated inflammatory liver disorder characterized by ongoing hepatocellular destruction, elevated serum immunoglobulin G (IgG) levels, circulating autoantibodies, and distinct histological features such as interface hepatitis2, 3. The disease exhibits a variable clinical spectrum, ranging from completely asymptomatic presentations discovered incidentally via abnormal liver biochemistry to fulminant hepatic failure with massive hepatocyte necrosis2, 4. Without prompt recognition and initiation of immunosuppressive therapy, the persistent immune-mediated attack drives continuous fibrogenesis, ultimately culminating in cirrhosis, portal hypertension, and end-stage liver disease3.

Etiology & Risk Factors

  • Genetic Predisposition: Strongly linked to the major histocompatibility complex (MHC), specifically human leukocyte antigen (HLA) alleles HLA-DRB1\*0301 (HLA-DR3) in younger populations with more severe disease and HLA-DRB1\*0401 (HLA-DR4) in older cohorts with milder courses and higher frequency of arthralgias.
  • Demographic Distribution: Demonstrates a marked female predominance, with a female-to-male ratio of approximately 4:1. The disease can manifest at any age, exhibiting bimodal peaks in adolescence and between the fourth and sixth decades of life2, 3.
  • Environmental and Infectious Triggers: Environmental agents, including certain xenobiotics, hepatotropic viruses (e.g., Epstein-Barr virus, hepatitis A or E), and medications (e.g., minocycline, nitrofurantoin), can act as molecular mimics or disrupt immune tolerance, precipitating acute flares in genetically susceptible hosts.
  • Autoimmune Comorbidities: Frequent coexistence with other autoimmune conditions, including Hashimoto thyroiditis, Graves disease, type 1 diabetes mellitus, celiac disease, ulcerative colitis, and rheumatoid arthritis.

Pathophysiology

The fundamental breakdown in autoimmune hepatitis involves a loss of immunological self-tolerance toward liver-specific and ubiquitous autoantigens. Genetic susceptibility alleles alter antigen presentation by antigen-presenting cells to naive CD4+ helper T cells. This aberrant presentation stimulates the expansion of autoreactive CD4+ and CD8+ T lymphocytes, which migrate into the hepatic parenchyma and periportal spaces6.

Activated CD8+ cytotoxic T cells directly target hepatocytes via perforin-granzyme-mediated lysis and Fas-FasL interactions, while CD4+ helper cells release proinflammatory cytokines (IFN-$\gamma$, TNF-$\alpha$, IL-17) that amplify the local inflammatory cascade. Concurrently, B lymphocytes undergo hyperactivation under T-cell influence, differentiating into plasma cells that secrete large quantities of immunoglobulins (hypergammaglobulinemia $\text{IgG}$) and produce circulating diagnostic autoantibodies. Unchecked, this persistent cellular and cytokine-driven assault leads to piecemeal necrosis (interface hepatitis), breakdown of the limiting plate, sinusoidal fibrosis, and progressive structural remodeling of the hepatic architecture3, 6.

Autoimmune hepatitis — Pathophysiological Cascade & Clinical Flowchart 1 Trigger / Primary Insult Genetic predisposition (HLA-DR3/DR4) interacting with environmental triggers or viral mimics 2 Cellular / Pathophysiological Cascade Breakdown of immune tolerance leading to T-cell-mediated cytotoxicity against hepatocytes and plasma cell infiltration 3 Target Organ / Structural Change Periportal inflammation, interface hepatitis, bridging fibrosis, and eventual progression to cirrhosis 4 Hallmark Clinical & Diagnostic Manifestation Elevated aminotransferases, hypergammaglobulinemia, positive ANA, ASMA, or anti-LKM1 autoantibodies 5 Complications if Untreated & Therapeutic Target Portal hypertension, hepatocellular carcinoma, or end-stage liver failure requiring immunosuppression or transplant

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: The clinical onset is highly heterogeneous. Up to one-third of patients are asymptomatic at diagnosis, identified solely by incidental transaminase elevations. Symptomatic patients commonly report insidious fatigue, malaise, right upper quadrant abdominal discomfort, arthralgias (typically affecting small joints without permanent deformity), anorexia, and nausea. A significant subset presents with an acute hepatitis-like picture characterized by prominent jaundice, dark urine, and pale stools.
  • Physical Examination & Named Clinical Signs: Physical findings vary depending on disease stage. Early disease may reveal mild hepatomegaly. Advanced disease or established cirrhosis manifests signs of chronic liver failure and portal hypertension, including cutaneous spider angiomas, palmar erythema, jaundice, splenomegaly, caput medusae, ascites, and asterixis in cases of hepatic encephalopathy.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationPercutaneous or transjugular liver biopsy demonstrating dense lymphoplasmacytic infiltration of the portal tracts, interface hepatitis (piecemeal necrosis spilling into the hepatic lobule), emperipolesis, and rosetting of hepatocytes.
Laboratory PanelMarked elevation of serum aminotransferases (AST and ALT, often > 5$\times$ ULN), disproportionately modest elevation of alkaline phosphatase (ALP < 2$\times$ ULN), hypergammaglobulinemia (elevated serum $\text{IgG}$ > 1.5$\times$ ULN), and positive serology (ANA, ASMA, anti-LKM1, or anti-SLA).
Imaging / Radiology (X-ray, US, CT, MRI)Abdominal ultrasound or cross-sectional imaging may show hepatomegaly, coarsened echotexture, or structural hallmarks of cirrhosis and portal hypertension (nodular liver contour, splenomegaly, recanalized umbilical vein, ascites).
ECG / Histopathology / ProceduralHistopathologic evaluation is essential to grade inflammatory activity and stage fibrosis (e.g., METAVIR or Ishak scoring systems), ruling out steatohepatitis, viral etiologies, or drug-induced liver injury.

Staging, Classification & Clinical Scoring Systems

Criterion / Score Component Clinical Threshold, Points & Management Implication
Simplified Diagnostic Criteria (Hegarty/International Autoimmune Hepatitis Group)Assesses ANA/ASMA titer ($\ge 1:40 = 1$ pt; $\ge 1:80 = 2$ pts), serum $\text{IgG}$ level (> ULN = 1 pt; > 1.1 $\times$ ULN = 2 pts), liver histology (compatible = 1 pt; typical = 2 pts), and absence of viral hepatitis. Total score $\ge 6$ indicates probable AIH; $\ge 7$ indicates definite AIH.
AIH Subtypes (Type 1 vs. Type 2)Type 1: Positive for Anti-Nuclear Antibodies (ANA) and/or Anti-Smooth Muscle Antibodies (ASMA); affects all ages. Type 2: Positive for Anti-Liver Kidney Microsomal type 1 (anti-LKM1) and/or Anti-Liver Cytosol type 1 (anti-LC1); more aggressive course, typical in children and young adults.
Revised Original Scoring SystemComprehensive point-based diagnostic algorithm utilized in complex or seronegative cases, factoring in age, gender, alkaline-to-aminotransferase ratio, globulin levels, autoantibody titers, viral markers, drug history, and histologic features.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Viral Hepatitis (B and C)Confirmed via active serological screening panels (HBsAg, anti-HBc, HCV RNA PCR). Histology may show lobular disarray and ground-glass hepatocytes rather than prominent plasma cell-rich interface hepatitis.
Drug-Induced Liver Injury (DILI)Detailed medication reconciliation is critical. Certain agents (e.g., minocycline, nitroferantoin, checkpoint inhibitors) can induce an autoimmune-like phenotype that may resolve upon drug withdrawal, though sometimes requiring temporary immunosuppression.
Non-Alcoholic Fatty Liver Disease (NAFLD) / MASHAssociated with metabolic syndrome, insulin resistance, central obesity, and imaging evidence of hepatic steatosis. Histology reveals ballooning degeneration, lobular inflammation, and Mallory-Denk bodies without predominant plasma cell infiltrates.
Primary Biliary Cholangitis (PBC) & Primary Sclerosing Cholangitis (PSC)Characterized by a cholestatic biochemical profile (markedly elevated ALP and $\gamma\text{GT}$). PBC features anti-mitochondrial antibodies (AMA) and nonsuppurative destructive cholangitis; PSC features multifocal biliary strictures on MRCP. (Overlap syndromes can occasionally coexist).

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Patients presenting with acute liver failure or decompensated cirrhosis require immediate admission to an intensive care unit or specialized hepatology ward. Hemodynamic monitoring, coagulopathy correction with vitamin K or fresh frozen plasma, and close surveillance for hepatic encephalopathy are mandatory. Emergency evaluation for liver transplantation is required for those failing to respond to medical therapy.
  • First-Line Medical / Pharmacological Therapy: The primary objective is to induce and maintain complete biochemical and histological remission3.
    • Induction Protocol: Prednisone initiated at 1 mg/kg/day orally (maximum 60 mg/day) as monotherapy, OR a combined regimen of a lower starting dose of prednisone (0.5 mg/kg/day, e.g., 30 mg/day) combined with azathioprine (1–2 mg/kg/day oral). Combination therapy is preferred to minimize corticosteroid-related adverse effects (osteoporosis, weight gain, glucose intolerance, psychiatric disturbances).
    • Maintenance Protocol: Following clinical and biochemical normalization (usually achieved within 3 to 6 months), corticosteroids are gradually tapered to the lowest effective dose or withdrawn entirely, while maintaining azathioprine monotherapy (1–2 mg/kg/day).
    • Alternative Agents: For patients with azathioprine intolerance or thiopurine methyltransferase (TPMT) deficiency, mycophenolate mofetil (1,000–2,000 mg/day divided twice daily) serves as a validated second-line steroid-sparing agent. Calcineurin inhibitors (tacrolimus, cyclosporine) are utilized in refractory cases7.
  • Surgical / Interventional Indications: Orthotopic liver transplantation is indicated for patients with decompensated cirrhosis, hepatocellular carcinoma meeting Milan criteria, or acute liver failure unresponsive to high-dose corticosteroid rescue. Post-transplant recurrence occurs in a subset of patients but generally responds well to adjusted immunosuppression.

Complications & Prognosis

  • Complications: Uncontrolled inflammation drives progressive extracellular matrix deposition, culminating in cirrhosis, portal hypertension, esophageal variceal hemorrhage, refractory ascites, hepatic encephalopathy, hepatorenal syndrome, and an increased risk of hepatocellular carcinoma. Long-term systemic corticosteroid therapy carries risks of iatrogenic Cushing syndrome, secondary osteoporosis, aseptic necrosis of the femoral head, and metabolic complications.
  • Prognosis: Untreated severe autoimmune hepatitis carries a dismal prognosis, with a 5-year mortality rate exceeding 50% in symptomatic cases. Conversely, prompt and sustained response to immunosuppressive therapy is associated with excellent long-term survival rates comparable to the general population, although complete histological remission and successful drug withdrawal are achieved in fewer than 20% of patients after sustained biochemical remission, making lifelong maintenance therapy necessary for the majority3, 7.